Haematopoietic Stem Cell Transplantation in Children Shifts the Coagulation System towards a Pro-Coagulant State

Satu Långström; Minna Koskenvuo; Pasi Huttunen; Riitta Lassila; Mervi Taskinen; Susanna Ranta; Markku Heikinheimo; Anne Mäkipernaa

doi:10.1055/s-0038-1661394

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(08): 1390-1396
DOI: 10.1055/s-0038-1661394

Coagulation and Fibrinolysis

Georg Thieme Verlag KG Stuttgart · New York

Haematopoietic Stem Cell Transplantation in Children Shifts the Coagulation System towards a Pro-Coagulant State

Satu Långström

¹Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

,

Minna Koskenvuo

¹Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

,

Pasi Huttunen

¹Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

,

Riitta Lassila

²Unit for Coagulation Disorders, Department of Haematology, Comprehensive Care Center and Cancer Center, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

,

Mervi Taskinen

¹Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

,

Susanna Ranta

³Astrid Lindgren Children's Hospital, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden

,

Markku Heikinheimo

¹Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

,

Anne Mäkipernaa

²Unit for Coagulation Disorders, Department of Haematology, Comprehensive Care Center and Cancer Center, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland

› Author Affiliations

Abstract

Coagulation system is disturbed by several mechanisms after allogeneic haematopoietic stem cell transplantation (HSCT). We evaluated the effect of HSCT on coagulation system by various conventional and investigational methods in 30 children and adolescents who received HSCT due to haematological malignancies. Pro-thrombin fragment 1 + 2, a specific measure of thrombin generation, and von Willebrand factor, a measure of endothelial activation, increased after conditioning treatment, and remained elevated until 3 months after HSCT (p < 0.05 for all comparisons to pre-conditioning treatment). D-dimer, a measure of fibrin turnover, was elevated from the second week onwards until 4 weeks after HSCT (p < 0.05). Endogenous thrombin potential was increased after conditioning, and at 2 weeks after HSCT (p < 0.05). Furthermore, the activities of acute phase reactants fibrinogen and coagulation factor VIII were increased (p < 0.05 for all comparisons to pre-conditioning treatment) from the first week onwards up to 3 weeks and 3 months after HSCT, respectively. Taken together, paediatric patients receiving HSCT demonstrate distinct and prolonged variations in the coagulation system towards a pro-coagulant state. This shift is of importance when estimating the risk of haemostatic and thrombotic complications in these children.

Keywords

coagulation - paediatric - stem cell transplantation - haematological malignancy - thrombin

Full Text

References

References
1 Peters C, Schrappe M, von Stackelberg A. , et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial. J Clin Oncol 2015; 33 (11) 1265-1274
2 Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011; 46 (12) 1495-1502
3 Luft T, Dietrich S, Falk C. , et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118 (06) 1685-1692
4 Pinomäki A, Volin L, Joutsi-Korhonen L. , et al. Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD. Bone Marrow Transplant 2010; 45 (04) 730-737
5 Levi M, van der Poll T. A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost 2014; 40 (08) 874-880
6 Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood 2014; 123 (17) 2605-2613
7 Squizzato A, Gerdes VEA, Büller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005; 93 (03) 403-410
8 Cesaro S, Tridello G, Pillon M. , et al. A prospective study on the predictive value of plasma BK virus-DNA load for hemorrhagic cystitis in pediatric patients after stem cell transplantation. J Pediatric Infect Dis Soc 2015; 4 (02) 134-142
9 Robertson JD. Pediatric transplantation: preventing thrombosis. J Thromb Haemost 2015; 13 (Suppl. 01) S351-S361
10 Brandão LR, Kletzel M, Boulad F. , et al. A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50 (06) 1240-1246
11 Jevtic D, Zecevic Z, Veljkovic D, Dopsaj V, Radojicic Z, Elezovic I. Veno-occlusive disease in pediatric patients after hematopoietic stem cell transplantation: relevance of activated coagulation and fibrinolysis markers and natural anticoagulants. J Pediatr Hematol Oncol 2011; 33 (03) 227-234
12 Brown SA, Davies SV, Fegan C. , et al. Haemostatic and fibrinolytic responses to bone marrow transplantation. Br J Haematol 1999; 104 (03) 468-474
13 Hingorani SR, Seidel K, Pao E, Lawler R, McDonald GB. Markers of coagulation activation and acute kidney injury in patients after hematopoietic cell transplantation. Bone Marrow Transplant 2015; 50 (05) 715-720
14 Hemker HC, Giesen P, Al Dieri R. , et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
15 Corbacioglu S, Cesaro S, Faraci M. , et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012; 379 (9823): 1301-1309
16 Przepiorka D, Weisdorf D, Martin P. , et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15 (06) 825-828
17 Pihusch M, Wegner H, Goehring P. , et al. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36 (07) 631-637
18 Iguchi A, Kobayashi R, Kaneda M, Kobayashi K. Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation. Pediatr Blood Cancer 2010; 54 (03) 437-443
19 Przybyla B, Pinomäki A, Petäjä J. , et al. Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - a longitudinal study. PLoS One 2017; 12 (12) e0190007
20 Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned?. Blood Rev 2012; 26 (05) 197-203
21 Bowie EJ, Solberg Jr LA, Fass DN. , et al. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. J Clin Invest 1986; 78 (01) 26-30
22 Nadir Y, Brenner B. Thrombotic complications associated with stem cell transplantation. Blood Rev 2012; 26 (05) 183-187
23 de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost 2010; 36 (01) 7-17
24 Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D. The factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost 2000; 84 (02) 216-222
25 Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms–the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71 (06) 719-722
26 Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012; 157 (06) 653-663
27 Timp JF, Lijfering WM, Flinterman LE. , et al. Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study. J Thromb Haemost 2015; 13 (10) 1823-1832
28 Liang HPH, Kerschen EJ, Basu S. , et al. Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood 2015; 126 (21) 2415-2423
29 Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003; 17 (08) 1636-1642
30 Palomo M, Diaz-Ricart M, Rovira M, Escolar G, Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (04) 497-506
31 Tuckuviene R, Ranta S, Albertsen BK. , et al. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study. J Thromb Haemost 2016; 14 (03) 485-494
32 van Ommen CH, Chan AKC. Supportive care in pediatric cancer: the road to prevention of thrombosis. Semin Thromb Hemost 2014; 40 (03) 371-381
33 Vidal E, Sharathkumar A, Glover J, Faustino EV. Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (07) 1096-1109